Azenta, Inc. (LON:0HQ1)
Market Cap | 1.00B |
Revenue (ttm) | 488.17M |
Net Income (ttm) | -81.45M |
Shares Out | n/a |
EPS (ttm) | -1.76 |
PE Ratio | n/a |
Forward PE | 38.16 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1 |
Average Volume | 92 |
Open | n/a |
Previous Close | n/a |
Day's Range | n/a |
52-Week Range | 25.12 - 55.00 |
Beta | 1.65 |
RSI | 44.49 |
Earnings Date | Nov 10, 2025 |
About Azenta
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in the United States, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates through three reportable segments: Sample Management Solutions, Multiomics, and B Medical Systems. The Sample Management Solutions segment provides sample management products and solutions, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments,... [Read more]
Financial Performance
In 2024, Azenta's revenue was $656.32 million, a decrease of -1.32% compared to the previous year's $665.07 million. Losses were -$164.17 million, 1051.5% more than in 2023.
Financial numbers in USD Financial StatementsNews
Azenta reaffirms 3%–5% organic growth and 300bps margin expansion for 2025 as operational turnaround advances
Azenta, Inc. 2025 Q3 - Results - Earnings Call Presentation
Azenta, Inc. (AZTA) Q3 2025 Earnings Call Transcript

Azenta (AZTA) Q3 EPS Jumps 36%
Azenta Non-GAAP EPS of $0.19 beats by $0.05, revenue of $144M misses by $5.81M

Azenta Reports Third Quarter Results for Fiscal 2025, Ended June 30, 2025; Reiterates Full Year Fiscal 2025 Guidance
BURLINGTON, Mass. , Aug. 5, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2025.

Azenta Life Sciences Partners with Frenova, a Division of Fresenius Medical Care, and Nephronomics to Advance Genomic Research in Nephrology
BURLINGTON, Mass. , July 31, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has entered a collaboration with Frenova, a division of Fresenius Medical Care, and Nephronomics, ...

Fresenius Medical Care's Third-Party Clinical Research Organization Frenova Announces Strategic Collaboration Advancing Genomics-Driven, Precision Kidney Disease Care
Frenova and Nephronomics, a renal precision company co-founded by Fresenius Medical Care, initiate collaboration with GENEWIZ by Azenta Life Sciences Provides vital insights through sophisticated geno...

Azenta to Participate in 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
BURLINGTON, Mass. , July 30, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conf...

Azenta Announces Fiscal 2025 Third Quarter Earnings Conference Call and Webcast
BURLINGTON, Mass. , July 23, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal third quarter 2025 earnings which ended on June 30, 2025, on Tuesday August 5, 2025, before the marke...
Azenta: Down 40% And Still Not Compelling

Azenta Life Sciences and Form Bio Announce Strategic Partnership to Advance AAV Gene Therapy Development
Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster. BURLINGTON, Mass.
Azenta targets 3%-5% organic growth and expands automation initiatives for FY2025
Azenta, Inc. (AZTA) Q2 2025 Earnings Call Transcript
Azenta, Inc. 2025 Q2 - Results - Earnings Call Presentation

Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025
BURLINGTON, Mass. , May 7, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the second quarter ended March 31, 2025.

Insights Ahead: Azenta's Quarterly Earnings
Azenta (NASDAQ: AZTA) is set to give its latest quarterly earnings report on Wednesday, 2025-05-07. Here's what investors need to know before the announcement. Analysts estimate that Azenta will repo...
Azenta Q2 2025 Earnings Preview

Azenta Announces Fiscal 2025 Second Quarter Earnings Conference Call and Webcast
BURLINGTON, Mass. , April 24, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal second quarter 2025 earnings which ended on March 31, 2025, on Wednesday May 7, 2025, before the mar...

Azenta: Life Science Business Failing To Come To Life
Struggling to grow, Azenta faces challenges like declining sales and CEO departure.

Azenta Publishes its 2024 Environmental, Social, & Governance (ESG) Report
BURLINGTON, Mass. , March 24, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the publication of its annual Environmental, Social, & Governance ("ESG") report, highlighting the Compan...

Azenta to Participate in the Virtual KeyBanc Capital Markets Healthcare Forum
BURLINGTON, Mass. , March 10, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) announced that Lawrence Y.
Azenta Inc (AZTA) Trading Down 5.56% on Feb 27
Azenta Inc (AZTA) Trading Down 5.56% on Feb 27
Azenta Inc (AZTA) Shares Down 4.06% on Feb 11
Azenta Inc (AZTA) Shares Down 4.06% on Feb 11